Inhibition of angiogenic attributes by decursin in endothelial cells and ex vivo rat aortic ring angiogenesis model

Indian Journal of Experimental Biology

Volumn 49, Issue 11, 2011, Pages 848-856

  Bhat, Tariq A ^a   Moon, Jung S ^b   Lee, Sookyeon ^b   Yim, Dongsool ^b   Singh, Rana P ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b Sahmyook University   (South Korea)

Author keywords

Angioprevention; Decursin; Tumor angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; BENZOPYRAN DERIVATIVE; BUTYRIC ACID DERIVATIVE; DECURSIN; GELATINASE A; GELATINASE B;

ANGIOGENESIS; ANIMAL; ANIMAL MODEL; AORTA; ARTICLE; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; ENZYMOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); RAT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; AORTA; BENZOPYRANS; BUTYRIC ACIDS; CELL MOVEMENT; ENDOTHELIAL CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MODELS, ANIMAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RATS;

RATTUS;

EID: 80355149328     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Gimbrone M A Jr, Leapman S B, Cotran R S & Folkman J, Tumor dormancy in vivo by prevention of neovascularization, J Exp Med, 136 (1972) 261.
2. Folkman J, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285 (1971) 1182.
3. Folkman J, Anti-angiogenesis: new concept for therapy of solid tumors, Ann Surg, 175 (1972) 409.
4. Bhat T A & Singh R P, Tumor angiogenesis--a potential target in cancer chemoprevention, Food Chem Toxicol, 46 (2008) 1334.
5. Surh Y-J, Cancer chemoprevention with dietary Phytochemicals, Nature Rev Cancer, 3 (2003) 768.
6. Tosetti F, Ferrari N, Flora S D & Albini A, 'Angioprevention': angiogenesis is a common and key target for cancer chemopreventive agents, FASEB J, 16 (2002) 2.
7. Singh R P, Gu M & Agarwal R, Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis, Cancer Res, 68 (2008) 2043.
8. Singh R P, Raina K, Sharma G & Agarwal R, Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice, Clin Cancer Res, 14 (2008) 7773.
9. Agarwal C, Singh R P, Dhanalakshmi S & Agarwal R, Antiangiogenic efficacy of grape seed extract in endothelial cells, Oncol Rep, 11 (2004) 681.
10. Singh R P, Sharma G, Mallikarjuna G U, Dhanalakshmi S, Agarwal C & Agarwal R, In vivo suppression of hormonerefractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor, Clin Cancer Res, 10 (2004) 244.
11. Chen Y, Zhang Y X, Li M H, Zhao W M, Shi Y H, Miao Z H, Zhang X W, Lin L P & Ding J, Antiangiogenic activity of 11,11'-dideoxyverticillin, a natural product isolated from the fungus Shiraia bambusicola, Biochem Biophys Res Commun, 329 (2005) 1334.
12. Kim W J, Lee S J, Choi Y D & Moon S K, Decursin inhibits growth of human bladder and colon cancer cells via apoptosis, G1-phase cell cycle arrest and extracellular signalregulated kinase activation, Int J Mol Med, 25 (2010) 635.
13. Yim D, Singh R P, Agarwal C, Lee S, Chi H & Agarwal R, A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells, Cancer Res, 65 (2005) 1035.
14. Song G Y, Lee J H, Cho M, Park B S, Kim D E & Oh S, Decursin suppresses human androgen-independent PC3 prostate cancer cell proliferation by promoting the degradation of beta-catenin, Mol Pharmacol, 72 (2007) 1599.
15. Jiang C, Guo J, Wang Z, Xiao B, Lee H J, Lee E O, Kim S H & Lu J, Decursin and decursinol angelate inhibit estrogenstimulated and estrogen-independent growth and survival of breast cancer cells, Breast Cancer Res, 9 (2007) R77.
16. Jung M H, Lee S H, Ahn E M & Lee Y M, Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway, Carcinogenesis, 30 (2009) 655.
17. Son S H, Kim M J, Chung W Y, Son J A, Kim Y S, Kim Y C, Kang S S, Lee S K & Park K K, Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase, Cancer Lett, 280 (2009) 86.
18. Kim J H, Kim J H, Lee Y M, Ahn E M, Kim K W & Yu Y S, Decursin inhibits retinal neovascularization via suppression of VEGFR-2 activation, Mol Vis, 15 (2009) 1868.
19. Singh R P, Dhanalakshmi S, Agarwal C & Agarwal R, Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy, Oncogene, 24 (2005) 1188.
20. Singh R P & Agarwal R, Mechanisms of action of novel agents for prostate cancer chemoprevention, Endocr Relat Cancer, 13 (2006) 751.
21. Jacoby D B, Dyskin E, Yalcin M, Kesavan K, Dahlberg W, Ratliff J, Johnson E W & Mousa S A, Potent pleiotropic anti-angiogenic effects of TM601, a synthetic chlorotoxin peptide, Anticancer Res, 30 (2010) 39.
22. Gialeli C, Theocharis A D & Karamanos N K, Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting, FEBS J, 278 (2011) 16.
23. William G & Stetler-Stevenson, Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention, J Clin Invest, 103 (1999) 1237.
24. Krüger E A & Figg W D, Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay, Clin Cancer Res, 7 (2001) 1867.